From Bettina Bauer, Vice President, US HIV Treatment and Prevention, Gilead Sciences In 2022, there were up to 1.2 million ...

Serious questions are being raised about what led to the limited supply of crucial HIV medication, prompting the Health ...

LAHORE: In what appeared to be a distressing incident, a kidney-failure patient died while 30 others contracted Human ...

Nebraska football head coach says that bringing Dana Holgorsen aboard as offensive coordinator is all about getting the ...

Westport failed to provide a resident medication to treat advanced HIV for three weeks, resulting in "significant medication ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

Revolutionary new HIV drugs are being made available in 120 low-income countries, but many important populations are being left out. Sophie Cousins reports.

A University of New Mexico researcher and assistant professor is breaking barriers in the health community for fellow Native Americans. Hailing from the Diné Nation, Crystal Lee has been researching ...

The study from Tulane University found that those living in once-redlined neighborhoods see 15% longer delays in achieving successful viral suppression of HIV compared to those in non-redlined areas.

More (and smarter) prevention: One of the amazing things about Ryan White (the young hero and the landmark HIV legislation he ...

Highly effective treatments for HIV have existed since the mid-1990s. But while these treatments keep people healthy, we do not yet have a safe and scalable way to completely rid the body of the virus ...

A new study from Tulane University finds that historical race-based lending practices are still impacting health today, linking these discriminatory policies to delays in effective HIV treatment ...